MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

32.30 +0.16 (+0.50%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Viking Therapeutics Ignites Retail-Trader Frenzy Amid Deal Speculation, Upcoming Trial Catalysts ↗
Via Stocktwits
News headline image
The Best Stocks to Invest $1,000 in Right Now ↗
Buying these three stocks offers you instant diversification. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Why This Beaten-Down GLP-1 Stock Could Be a Steal ↗
There's more to this company than its performance on the stock market this year suggests. 
Via The Motley Fool
News headline image
Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering. ↗
Investors once speculated that Pfizer might consider acquiring Viking. 
Via The Motley Fool
News headline image
Viking Therapeutics Stock Gets Boost From Pfizer-Metsera Deal, Says BTIG — Retail Slams Rivals For Buying ‘Inferior Pipelines’ ↗
BTIG said Pfizer’s $7.3 billion Metsera acquisition sharpens its clinical updates and strategic optionality. 
Via Stocktwits
Viking Short Interest Hits 5-Year High After Weight-Loss Drug Stumble, But Retail Clings To Bullish Mood For Now ↗
Via Stocktwits
News headline image
Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market
The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
6 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Prediction: Viking Therapeutics Stock Will Double in Value Within the Next 12 Months ↗
Viking's stock took a beating last month, and it has opened up a glorious buying opportunity for investors. 
Via The Motley Fool
Topics Bankruptcy
News headline image
Biotech Breakouts: 3 Stocks With Massive Upside Potential ↗
Biotech stocks are highly volatile; however, these biotech stocks have key trial results this fall that could spark sharp moves and long-term growth potential 
Via MarketBeat
News headline image
Novo Nordisk Faces Headwinds: Competitive Pressures and Compounded Drugs Force Lowered Outlook
Copenhagen, Denmark – Novo Nordisk (NASDAQ: NVO), the pharmaceutical powerhouse synonymous with diabetes and obesity care, has significantly pared back its full-year sales and profit projections for... 
Via MarketMinute
Topics Economy Intellectual Property Law Enforcement
News headline image
Prediction: After a Tough Summer for Healthcare Stocks, These 2 Companies Can Make a Comeback ↗
One of them is already a leader in the market for weight management drugs, and the other could join this field. 
Via The Motley Fool
Topics ETFs
News headline image
Peering Into Viking Therapeutics's Recent Short Interest ↗
 
Via Benzinga
News headline image
Think It's Too Late to Buy This Leading Biotech Stock? Here's Why There's Still Time. ↗
The market may have been too quick to dismiss this biotech's pipeline prospects after a recent trial result. 
Via The Motley Fool
News headline image
Jim Cramer Expects Palantir To Reach New All-Time High ↗
Market analysts and financial commentators provide crucial guidance in the volatile investment landscape. Cramer says no to VKTX, but expects PLTR to go up. 
Via Benzinga
News headline image
Down 34%, Should You Buy the Dip on Viking Therapeutics? ↗
Viking aims to enter the billion-dollar weight loss drug market. 
Via The Motley Fool
News headline image
Prediction: These 2 Biotech Stocks Could Double in the Next 5 Years ↗
Both companies have made significant progress in recent years. 
Via The Motley Fool
News headline image
The Problem With Weight Loss Stocks ↗
There are new ways to tackle weight loss, but the stocks leading the way are lagging. 
Via The Motley Fool
Topics Economy
News headline image
2 Beaten-Down Stocks That Could Rocket 142% to 222% Higher, According to Wall Street Analysts ↗
Investment bank analysts up and down Wall Street are pounding the table on these stocks. 
Via The Motley Fool
News headline image
Why Viking Therapeutics Stock Popped Nearly 4% Today ↗
The company's obesity drug could have more potential than originally believed. 
Via The Motley Fool
News headline image
Billionaire Stanley Druckenmiller Just Bought the Dip on This Beaten-Down GLP-1 Stock (Hint: It's Not Eli Lilly or Novo Nordisk) ↗
Druckenmiller's Duquesne Family Office just scooped up a popular weight-loss stock. 
Via The Motley Fool
Topics Economy World Trade
News headline image
Why Is Viking Therapeutics Stock Crashing, and Is It a Buying Opportunity? ↗
The market for weight loss treatments is growing significantly and is forecast to continue increasing for several years. 
Via The Motley Fool
News headline image
Eli Lilly Scores Another Weight-Loss Win; Viking, Novo Stocks Slump ↗
Eli Lilly said Tuesday it will soon ask global regulators to approve its weight-loss pill following a third successful test. 
Via Investor's Business Daily
News headline image
Viking Therapeutics: What's Next? ↗
Viking's 40% crash over fixable dosing issues ignores its best-in-class 12.2% oral weight loss and Phase 3 momentum. 
Via The Motley Fool
News headline image
2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top Analysts ↗
These companies aren't performing as badly as their stock-market performances this year suggest. 
Via The Motley Fool
News headline image
Benzinga Bulls And Bears: Sunrun, Newegg, Walmart — And Powell Offers Rate Cut Hope ↗
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Here's Why Shares in Viking Therapeutics Crashed This Week ↗
The phase 2 trial results for its key drug didn't pan out quite as planned. 
Via The Motley Fool
News headline image
Market Brief: After Viking Therapeutics’ Results, Is Entera Bio the Oral Platform Play to Watch? (NASDAQ: ENTX)
Via AB Newswire
News headline image
Is Beaten-Down Viking Therapeutics Stock a Buy on the Dip? ↗
A disappointing result for its oral obesity candidate hammered the stock price. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story